Shire PLC Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (25)

Latest Posts

About This Stock More About This Stock
3 Undervalued Stocks To Invest In This Hot Market
Article By: Modest Money
Wednesday, July 19, 2017 1:20 PM EDT
I am going to highlight 3 undervalued stocks that still have room to grow, even though the market as a whole is near an all-time high.
In this article: SHPG, TSO, TEN
Read
5 Pharma & Biotech Stocks That Could Be Big Winners In Q2 Earnings
Article By: Arpita Dutt
Thursday, July 13, 2017 11:04 AM EDT
Drug stocks have bounced back this year with the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index gaining 18.6% and 10.8%, respectively, year-to-date (YTD).
In this article: MRK, GILD, LLY, CELG, SHPG
Read
E Bull In A China Bourse
Article By: Vivian Lewis
Saturday, June 24, 2017 2:16 PM EDT
It has become standard here in Britain to favor the FTSE 100 over broader UK indexes, because of its multinational company focus. Broader UK indexes depend on consumer spending which is down sharply.
In this article: AGU, ALV, BCS, CAE, CPA, CX, GSK, MXE, NOK, NVO, POT, SLB, SAN, DGRLY, DNACF, MXCHF, NPSNY, NTDOY, OROCF, RHHBY, SLFPY, TCTZF, INFY, SHPG, TEVA, RBGLY, FBASF, VRGDF
Read
E Trump's Kvittle
Article By: Vivian Lewis
Tuesday, May 23, 2017 12:24 AM EDT
The President should not be blamed for all the fall in our currency, because even before he hit the scene the US$ was up way over trend, and near its 1985 peak. To revive industry, as Trump proposes, he needs a cheaper currency.
In this article: , ALV, CZZ, F, GSK, MXE, TTM, VALE, VOD, CH, ANCUF, AQUNF, BKSHF, CGRIF, CMDXF, DLKGF, NPSNY, OROCF, PPEHF, TCTZF, BLRX, SHPG, TEVA, CGEN, CUBA, INPCF, BNTC, BNTCW
Read
Shire Ltd.'s $6 Billion Bet On Drug For Hereditary Angioedema Pays Off With Stellar Phase III Data
Article By: Lorimer Wilson
Thursday, May 18, 2017 1:54 PM EDT
Shire Ltd. bought Dyax for $6 billion in 2015 for its new drug for hereditary angioedema. Shire CEO Flemming Ornskov says their multi-billion dollar bet paid off with stellar Phase III data for the drug, now called lanadelumab.
In this article: SHPG
Read

PARTNER HEADLINES

Latest Tweets for $SHPG

No tweets yet!